Danvatirsen Plus Venetoclax

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML

What's the purpose of the trial?

This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).

Trial status

Accepting patients

Phase

Phase 1

Enrollment

Last Updated

1 month ago

Patient Screener

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Danvatirsen is a STAT3 targeting antisense oligonucleotide inhibitor that is being studied for use in several different kinds of cancer.
Venetoclax is a BCL-2 inhibitor that may work by blocking the action of the BCL-2 protein on some cancer cells which can lead to cell death.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Danvatirsen Monotherapy

Accepting patients

Danvatirsen + Venetoclax Combination Therapy

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.